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Summary
HNF4A gene mutations have been reported in cases of transient and persistent hyperinsulinaemic hypoglycaemia of 
infancy (HHI), particularly in families with adulthood diabetes. The case of a patient with HHI, liver impairment and renal 
tubulopathy due to a mutation in HNF4A is reported.
10.1530/EDM-16-0133ID: 16-0133
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•	 Urine specimen study in cases of HHI with diazoxide response is necessary to rule out specific metabolic conditions 
(l-3-hydroxyacyl-coenzyme A dehydrogenase deficiency) or tubular renal involvement.
•	 Hyperinsulinaemic hypoglycaemia due to the heterozygous mutation (p.Arg63Trp, c. 187C > T) in the HNF4A gene  
is associated with renal tubulopathy and liver involvement.
•	 Follow-up of patients diagnosed of HHI is mandatory to detect associated conditions.
Background
Hyperinsulinaemic hypoglycaemia of infancy (HHI) 
is the most frequent cause of persistent neonatal 
hypoglycaemia and hypoglycaemia in infancy and is 
caused by dysregulation in insulin secretion. Molecular 
bases are known in 50–60% of patients. To date, eleven 
genes have been implicated, and the most frequent 
cause is mutations in the genes encoding K-ATP channel 
subunits. Heterozygous mutations in the HNF4A gene 
have been reported in cases of transient and persistent 
HHI, particularly in families with neonatal hypoglycaemia 
and adulthood diabetes (1). The HNF4A gene encodes for 
the transcription factor hepatocyte nuclear 4a (HNF4a) 
that controls the expression of genes involved in glucose-
stimulated insulin secretion; its mutations were first known 
to be the cause of monogenic diabetes type 1 (MODY 1).
Herein, we present a case of hyperinsulinaemic 
hypoglycaemia with a mutation in HNF4A and renal 
tubulopathy; this characteristic phenotype has been 
recently described and very few cases have been 
reported worldwide.
Case presentation
A full-term large-for-gestational age boy (birth weight 
4250 g + 2.7 s.d. and length 55 cm + 3.29 s.d., head 
circumference 37 cm + 1.53 s.d.) developed hypoglycaemia 
on the first day of life. He was the second child of non-
consanguineous Caucasian parents. High carbohydrate 
i.v. administration was required to maintain euglycaemia 
(up to 17 mg/kg/min). Laboratory results showed 
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inappropriately low betahydroxybutyrate plasma levels 
(10.2 µmol/L), inappropriate insulin (6.1 IU/L) and 
C-peptide levels (2.7 ng/mL) and low cortisol levels 
(1.3 µg/dL and 5.2 µg/dL) in hypoglycaemia. The diagnosis 
of congenital hyperinsulinaemic hypoglycaemia was 
established. However, owing to low cortisol levels, 
hydrocortisone was started at 10 mg/m2/day without 
response. Function of other hypophyseal hormones was 
normal (thyroid hormones and testosterone levels were 
normal). Glucose in urine strips was detected on more 
than one occasion. Diazoxide was started at a dose of 
8 mg/kg/day 24 h after initiation of hydrocortisone and 
intravenous glucose could be stopped, normalising total 
carbohydrate requirements. As the patient did not present 
hypoglycaemia after 6 h of fasting, he was discharged at 
6  weeks of age on diazoxide at a dose of 6 mg/kg/day 
and with a nasogastric tube owing to feeding difficulties. 
Shortly after discharge, the diazoxide dose needed to 
be reduced owing to hyperglycaemia and was stopped 
at the age of three months since the glycaemia reached 
300 mg/dL even with a dose lower than 3 mg/kg/day. 
Treatment was based only on frequent feeds, both oral 
and by nasogastric tube that was maintained until the age 
of 18 months.
At six months of age, the patient had failure to thrive 
and mild hepatomegaly (3 cm below the costal margin). 
Laboratory tests showed high serum transaminase 
levels (AST 80–90 IU/L, ALT 40–50 IU/L and GGT 
60–100 IU/L). Laboratory tests for hepatotropic viruses 
and autoimmunity were negative. Liver biopsy was not 
performed as rises in liver enzymes were transient.
During follow-up, a progressive increase was observed 
in alkaline phosphatase (800–1384 IU/L), together with 
vitamin D deficiency (25OHD <20 ng/mL) with low serum 
phosphate (3–3.2 mg/dL) but normal calcium (9.7 mg/
dL) and magnesium (2.48 mg/dL) levels. Treatment with 
cholecalciferol was prescribed; however, the child gradually 
developed rickets with craniotabes, wrist widening, genu 
varum and motor impairment; findings on knee X-ray at 
12 months of age were typical of rickets (Fig. 1). Further 
complementary tests at 18 months of age revealed non-
gap metabolic acidosis (pH 7.27, bicarbonate 19.3) with 
acidified urine (pH 5.5) suggestive of proximal tubular 
acidosis, glycosuria with generalised aminoaciduria and 
tubular type proteinuria (β2 microglobulin >4 mg/L), in 
addition to hypophosphatemia of renal origin (serum P 
3.2 mg/dL and TRP 72%), hypercalciuria (UCa/Cr 0.5 mg/
mg and UCa 3.7 mg/kg/day) and carnitine deficiency (total 
carnitine 29.3 µmol/L). 25OHD levels were normal at 
that time (30 ng/mL), but PTH was elevated (155 pg/mL). 
Fanconi-type proximal complex tubulopathy was 
diagnosed. By that time, he had lost 5.8 standard 
deviations in height and 4 standard deviations in weight 
since birth (Fig.  2). Supplementary oral treatment with 
phosphate, sodium bicarbonate, carnitine and 1-alpha-
calcidiol was started immediately.
Investigation
Genetic testing for KCNJ11 and ABCC8 genes did not detect 
any mutation. Responsiveness to diazoxide and glucosuria 
pointed to HNF4A study, which revealed a heterozygous 
mutation in exon 2 of the HNF4A gene: p.Arg63Trp, 
Figure 1
Growth chart over first 3 years of life.
Figure 2
Wrist and knee X-rays at 16 months of age.
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c.187C > T (reference sequence: NM_175914.4). Both 
parents tested negative for the mutation.
Treatment
Diazoxide was started, and intravenous glucose could be 
stopped. On more than one occasion, the dose needed 
to be reduced owing to hyperglycaemia and had to be 
stopped by the age of three months. At six months of age, 
the patient was observed to have failure to thrive and mild 
hepatomegaly with slightly high serum transaminase 
levels. Tests for hepatotropic viruses and autoimmunity 
were negative. During follow-up, a progressive increase 
in alkaline phosphatase (800–1384 IU/L), vitamin D 
deficiency (25OHD: <20 ng/mL), low serum phosphate 
(3–3.2 mg/dL), but normal calcium and magnesium 
levels were observed. The child gradually developed 
rickets despite treatment with cholecalciferol. Further 
complementary tests revealed proximal tubular acidosis, 
glycosuria with generalised aminoaciduria and tubular 
type proteinuria, in addition to hypophosphataemia, 
hypercalciuria and carnitine deficiency. Fanconi-type 
proximal complex tubulopathy was diagnosed, and 
supplementary oral treatment was initiated. After 
treatment was started, the patient gained weight and 
height and recovered from his skeletal abnormalities.
Outcome and follow-up
At 3 years and 9 months of age, the patient has currently 
no signs of active rickets and, despite persistent 
Fanconi syndrome, his metabolic control is satisfactory. 
Cognitive and motor development are age adequate; 
weight (14.3 kg, −1.4 s.d.) and height (95 cm, −2 s.d.) have 
normalised with growth catch-up (2). He is now able to 
fast for eight hours; however, he remains on a 02:00 h 
intake that is being tapered. Minimal hepatomegaly 
and mildly increased transaminases (AST 98 IU/L, ALT 
63 IU/L at the last control) remain, with transient peaks 
during episodes of viral upper respiratory tract infection 
or gastroenteritis.
Discussion
The association between HHI and HNF4A mutations has 
been found in 0.5–2.4% of patients and was first reported 
by Pearson  et  al. (3). That study also reported a link 
between those mutations and macrosomia in a significant 
percentage of carriers. Nevertheless, it was not until 2010 
that the mutation in our patient (p.Arg63Trp, c.187C > T 
also reported as p.Arg76Trp (p.R76W), c.226C>T) was 
found to cause HHI, although the only patient reported 
to have it was not phenotypically described (4). A second 
case with the same mutation was reported in 2012. That 
patient had the same features as our patient, including 
the liver disorder, together with a liver biopsy, which 
showed abundant cytoplasmic glycogen with mild portal 
inflammation and fibrosis (5). In 2014, six more cases with 
our patient’s mutation were reported, including the first 
previously published in 2010 and without a phenotypical 
description. These six patients had no liver disorder 
and, unlike the patient we report, also had ‘atypical’ 
Fanconi syndrome with hypercalciuria with relative 
hypocalcaemia, hypermagnesaemia, nephrocalcinosis 
and renal impairment. Two patients had developed 
diabetes mellitus at 12 and 20  years of age respectively 
(6). Recently, Numakura et al. (7) and Improda et al. (8) 
each reported two additional cases, one of which had 
transient liver disease; the case described by Numukara 
presented hepatomegaly and raised serum transaminases 
at five months of age with normalisation at the age of 
three and that described by Improda had prolonged 
conjugated hyperbilirubinaemia which normalised over 
the first 3  months of life. Those authors suggested that 
transient liver enlargement could be a mutation-specific 
characteristic of p.R76W, taking into consideration that 
liver-specific HNF4A-knockout mice had hepatomegaly 
and that HNF4A regulates the expression of SLC2A2, a 
mutation which is a cause of Fanconi–Bickel syndrome 
(5, 7). However, not all the described patients with the 
R76W mutation presented liver impairment. Liver disease 
in our case has been permanent to date.
HNF-4α is known to regulate selected genes involved 
in insulin secretion; however, the precise molecular 
mechanisms by which HNF4A mutations cause insulin 
hypersecretion are not clearly understood (1). There 
appears to be a relationship with PPARa levels. PPARa is a 
transcription factor that regulates fatty acid β-oxidation; 
lower levels of this factor might reduce β-oxidation 
of fatty acids, thereby increasing the availability of 
lipid signalling molecules that are necessary for insulin 
exocytosis. This would lead to abnormal insulin secretion 
during fasting (9). 
Our case provides further evidence of the role of the 
HNF4A gene in the renal proximal tubule (PT). Potential 
pathogenic mechanisms accounting for the generalised PT 
dysfunction and thus the occurrence of Fanconi syndrome 
in patients with HNF4A mutations are unknown; however, 
the mutation-specific effect and involvement of major 
regulatory genes have been postulated (6). The HNF4A 
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R76W mutation causes an atypical dominant Fanconi 
syndrome in addition to the beta cell phenotype. Other 
inherited diseases causing Fanconi syndrome and neonatal-
onset hypoglycaemia, such as galactosaemia, tyrosinemia 
or mitochondrial diseases, were ruled out in our patient 
since his hypoglycaemia was due to hyperinsulinism. 
Further, Bickel–Fanconi syndrome is another Fanconi 
syndrome of hereditary origin with hypoglycaemia and 
liver impairment; however, symptoms usually appear 
later in infancy and hypoglycaemia is due to impaired 
liver release of glucose due to a GLUT2 deficiency. These 
facts also facilitated the differential diagnosis in our case.
The low cortisol levels found at diagnosis in our 
patient were noteworthy. This feature is relatively 
common among HHI patients and appears to be related 
to a lack of drive from the hypothalamic–pituitary axis, 
with inappropriately low plasma adrenocorticotropic 
hormone concentrations at the time of hypoglycaemia 
(10). The mechanism of this low response is not clear; 
the presence of K-ATP channels in the ventromedial 
hypothalamus (involved in glucose sensing) suggests that 
these channels might be closed in HHI, thereby impairing 
the counter-regulatory response to hypoglycaemia. 
However, this blunted counter-regulatory response 
has also been described in patients with no mutations 
in ABBC8/KCNJ11 genes. Hypoglycaemia-associated 
autonomic failure (HAAF) due to repeated hypoglycaemia 
has also been postulated. Further studies will be required 
to elucidate the counter-regulatory hormonal responses 
in patients with CHI.
The long-term follow-up of our patient should include 
glycaemic control in the search for the possible future 
onset of diabetes mellitus.
Our case adds to the understanding and subtleties 
of this rare and recently described mutation uniquely 
causing HHI and Fanconi syndrome. Our patient has 
permanent liver involvement and no atypical features in 
his FS, unlike the cases reported by Hamilton et al. (6).
It is clear that subtle initial laboratory results in our 
patient might have yielded clues and an earlier diagnosis 
could have been made. We hope this report will help to 
raise awareness of the possibility of FS and liver disorder 
when faced with children with HHI.
Patient’s perspective
Being parents, the most difficult thing for us was the 
uncertainty. It was at the Neonatal Care Unit where we were 
told about his first diagnosis: congenital hyperinsulinism. 
Our medical team told us that the causes and prognosis 
could be multiple. After a 6-week period at the Neonatal 
Unit, they let us take him home. Our endocrinologist, 
who has been accompanying us all these years, told us: 
‘please be patient’. Sometimes it has been difficult for us 
to keep calm, especially when he was 18 months old. We 
had the feeling that, beyond his first diagnosis, more and 
more new conditions were affecting him every now and 
then as he was growing up, such as proximal tubulopathy 
and raised transaminase levels. We could only ‘relax’ 
when the results of the genetic test arrived. The mutation 
of the gene HNFA4 was finally providing a reason for the 
whole clinical picture. Our son is now leading a normal 
life thanks to his regular feeding. The most difficult thing 
for us is to make him take his medicines, but as he was 
born with all these disorders, he is fully aware of the 
benefits of doing so, despite being just a 4-year-old child.
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